Company intelligence / Profile preview
Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd.
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
Overview
The company has multiple programs in clinical development, with its lead candidate Recombinant FGF21-Fc fusion Protein (AP025) in Phase 2 for NASH. AP026 (FGF21/GLP-1 bifunctional protein) is in Phase 1 for Type 2 Diabetes. AP017 is in Phase 1 for Hemophilia A. KL-A289 (targeting LAG3) is in development for Advanced Malignant Solid Neoplasm.
- Therapeutic areas
- OncologyEndocrinologyHematologyGastroenterologyCardiovascular
- Modalities
- Fusion proteinsMonoclonal antibodiesBispecific antibodiesBiological macromolecular drugs
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd..